InvestSMART

Pro Medicus Limited (ASX: PME) - Announcements

Current share price for PME : $191.600 14.41 (6.99%)+

ASX company news and announcements for Pro Medicus Limited (PME) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pro Medicus Limited (PME) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pro Medicus Limited (PME), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pro Medicus Limited (PME)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$20,016 PME - date correction 17 Nov 2017 11:13AM $7.250 $191.600 risen by 2,542.76%
$20,016 PME signs $18M - 7 year contract with Yale New Haven Health 17 Nov 2017 9:35AM $6.920 $191.600 risen by 2,668.79%
$20,016 Final Director's Interest Notice 14 Nov 2017 12:01PM $6.900 $191.600 risen by 2,676.81%
$20,016 Results of AGM - 2017 14 Nov 2017 11:59AM $6.900 $191.600 risen by 2,676.81%
$20,016 AGM Presentation 2017 14 Nov 2017 10:09AM $6.890 $191.600 risen by 2,680.84%
$20,016 PME announce retirement of Director 31 Oct 2017 9:47AM $6.710 $191.600 risen by 2,755.44%
$20,016 Annual Report 2017 13 Oct 2017 10:36AM $6.160 $191.600 risen by 3,010.39%
$20,016 Annual General Meeting Proxy Form 13 Oct 2017 10:10AM $6.130 $191.600 risen by 3,025.61%
$20,016 Notice of Annual General Meeting 13 Oct 2017 10:09AM $6.130 $191.600 risen by 3,025.61%
$20,016 Appendix 3B - Vesting of Performance Rights 25 Sep 2017 10:03AM $5.300 $191.600 risen by 3,515.09%
$20,016 FY17 Investor Presentation 11 Sep 2017 10:09AM $4.950 $191.600 risen by 3,770.71%
$20,016 PME appoints new Non-Executive Director (amended) 8 Sep 2017 10:28AM $4.910 $191.600 risen by 3,802.24%
$20,016 Appendix 3X - Initial Director's Interest Notice 8 Sep 2017 10:01AM $4.900 $191.600 risen by 3,810.20%
$20,016 PME appoints new Non-Executive Director 8 Sep 2017 9:48AM $4.900 $191.600 risen by 3,810.20%
$20,016 Open Briefing - CEO on FY17 results 18 Aug 2017 11:54AM $5.090 $191.600 risen by 3,664.24%
$20,016 Dividend/Distribution - PME 18 Aug 2017 9:50AM $4.890 $191.600 risen by 3,818.20%
$20,016 Appendix 4G and Corporate Governance Statement 18 Aug 2017 9:43AM $4.890 $191.600 risen by 3,818.20%
$20,016 PME delivers record profit 18 Aug 2017 9:42AM $4.890 $191.600 risen by 3,818.20%
$20,016 Full Year Statutory Accounts 18 Aug 2017 9:41AM $4.890 $191.600 risen by 3,818.20%
$20,016 Appendix 4E - Preliminary Final Report 18 Aug 2017 9:40AM $4.890 $191.600 risen by 3,818.20%
$20,016 PME brings Visage 7 Open Archive to North America 18 May 2017 9:25AM $5.300 $191.600 risen by 3,515.09%
$20,016 On market share buy-back 20 Mar 2017 11:56AM $5.250 $191.600 risen by 3,549.52%
$20,016 Mercy completes Visage implementation in record time 20 Mar 2017 9:29AM $4.860 $191.600 risen by 3,842.39%
$20,016 HY2017 Investor Presentation - March 2017 14 Mar 2017 9:16AM $4.330 $191.600 risen by 4,324.94%
$20,016 PME signs enterprise-wide RIS deal with Primary Healthcare 14 Mar 2017 8:31AM $4.330 $191.600 risen by 4,324.94%

476 - 500 of 679 results

Page 20 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.